Share on StockTwits

Athersys (NASDAQ:ATHX) EVP Robert J. Deans unloaded 5,080 shares of the stock in a transaction dated Thursday, June 19th. The shares were sold at an average price of $1.63, for a total value of $8,280.40. Following the completion of the transaction, the executive vice president now directly owns 468,195 shares of the company’s stock, valued at approximately $763,158. The transaction was disclosed in a document filed with the SEC, which is available at this link.

A number of research firms have recently commented on ATHX. Analysts at Edison Investment Research reiterated a “neutral” rating on shares of Athersys in a research note on Tuesday, May 6th. Analysts at First Analysis initiated coverage on shares of Athersys in a research note on Tuesday, April 29th. They set an “overweight” rating and a $5.00 price target on the stock.

Athersys (NASDAQ:ATHX) opened at 1.58 on Monday. Athersys has a 52 week low of $1.08 and a 52 week high of $4.33. The stock has a 50-day moving average of $1.58 and a 200-day moving average of $2.77. The company’s market cap is $121.7 million.

Athersys (NASDAQ:ATHX) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.09) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.10) by $0.01. The company had revenue of $0.71 million for the quarter, compared to the consensus estimate of $0.66 million. Athersys’s revenue was up 116.9% compared to the same quarter last year. On average, analysts predict that Athersys will post $-0.40 earnings per share for the current fiscal year.

Athersys, Inc is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and improve the quality of human life.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.